BLA 761450 · Shanghai Henlius Biotech
Poherdy
Pertuzumab-Dpzb · Intravenous
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Nov 13, 2025
Approved uses
1
Original approval plus efficacy supplements
Registered trials
381
92 Phase 3, 91 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- POHERDY · PERTUZUMAB-DPZB 420MG/14ML(30MG/ML) · INJECTABLE, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Pertuzumab" as an intervention, any sponsor and status, largest first.
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruiting
National Cancer Institute (NCI)NIH
NCT02465060 · 6,452 participants (planned) · Start Aug 17, 2015 · Primary completion Dec 31, 2027
Drug: Adavosertib; Afatinib and 30 more · For: Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Bladder Carcinoma and 49 more
Sites: Birmingham, Alabama; Fairhope, Alabama; Mobile, Alabama · 1,410 sites in all
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerPivotal-lookingRecruiting
QuantumLeap Healthcare CollaborativeAcademic, hospital or other
NCT01042379 · 5,000 participants (planned) · Start Mar 1, 2010 · Primary completion Dec 2030
Drug: Standard Therapy; AMG 386 with or without Trastuzumab and 44 more · For: Breast Neoplasms; Breast Cancer; Breast Tumors and 8 more
Sites: Birmingham, Alabama; Scottsdale, Arizona; Tucson, Arizona · 42 sites in all
- A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast CancerPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT01358877 · 4,804 participants · Start Nov 8, 2011 · Primary completion Dec 19, 2016
Drug: 5-Fluorouracil; Carboplatin and 8 more · For: Breast Cancer
Sites: Scottsdale, Arizona; Everett, California; Greenbrae, California · 546 sites in all
American Society of Clinical OncologyAcademic, hospital or other
NCT02693535 · 4,200 participants (planned) · Start Mar 14, 2016 · Primary completion Dec 31, 2027
Drug: Sunitinib (CLOSED TO ENROLLMENT); Trastuzumab and Pertuzumab (CLOSED TO ENROLLMENT) and 10 more · For: Lymphoma, Non-Hodgkin; Multiple Myeloma; Advanced Solid Tumors
Sites: Birmingham, Alabama; Phoenix, Arizona; Auburn, California · 181 sites in all
Oslo University HospitalAcademic, hospital or other
NCT04817956 · 3,000 participants (planned) · Start Apr 1, 2021 · Primary completion Mar 30, 2040
Drug: Atezolizumab · For: Cancer Metastatic
Sites: Ålesund, Norway; Bergen, Norway; Bodø, Norway · 17 sites in all
- A Study for the Adjuvant Treatment of Breast CancerPivotal-lookingRecruiting
Second Affiliated Hospital, Zhejiang University, School of MedicineAcademic, hospital or other
NCT05420467 · 2,413 participants (planned) · Start Jul 10, 2022 · Primary completion Jul 10, 2027
Drug: Docetaxel; Carboplatin and 10 more · For: Breast Cancer
Sites: Hangzhou, China
- CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted TherapyActive, not recruiting
ECOG-ACRIN Cancer Research GroupResearch network
NCT04266249 · 2,175 participants · Start Mar 13, 2020 · Primary completion Oct 31, 2027
Drug: Docetaxel; Nab-paclitaxel and 4 more · For: Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8 and 6 more
Sites: Birmingham, Alabama; Anchorage, Alaska; Fairbanks, Alaska · 1,008 sites in all
- A Multicenter Phase III Clinical Study and Translational Research on Adaptive Neoadjuvant Therapy of De-escalation and Escalation for HER2-Positive Breast Cancer Based on Multi-Omics Response Evaluation ModelPivotal-lookingNot yet recruiting
Cancer Institute and Hospital, Chinese Academy of Medical SciencesAcademic, hospital or other
NCT07239271 · 2,000 participants (planned) · Start Nov 16, 2025 · Primary completion Dec 2027
Drug: The control group; Adaptive therapy of de-escalation and escalation based on imaging and molecular analysis for predicting response · For: Patients With HER2-positive Breast Cancer (BC) Suitable for Neoadjuvant Therapy
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial.
Harbeck N, Modi S, Pusztai L, et al. · Ann Oncol 2026 · Clinical Trial, Phase III, Multicenter Study
- Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer.
Tolaney SM, Jiang Z, Zhang Q, et al. · N Engl J Med 2026 · Clinical Trial, Phase III, Equivalence Trial
- Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.
Swain SM, Miles D, Kim SB, et al. · Lancet Oncol 2020 · Clinical Trial, Phase III, Multicenter Study
- Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial.
Hurvitz SA, Hegg R, Chung WP, et al. · Lancet 2023 · Randomized Controlled Trial, Multicenter Study
- HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer.
Dieras V, Curigliano G, Martin M, et al. · J Clin Oncol 2026 · Clinical Trial, Phase III, Randomized Controlled Trial
- Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.
von Minckwitz G, Procter M, de Azambuja E, et al. · N Engl J Med 2017 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Shanghai Henlius Biotech
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.